X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1121) 1121
humans (1075) 1075
b7-h1 antigen - antagonists & inhibitors (804) 804
immunotherapy (607) 607
programmed cell death 1 receptor - antagonists & inhibitors (571) 571
oncology (568) 568
animals (492) 492
cancer (427) 427
female (373) 373
b7-h1 antigen - immunology (357) 357
b7-h1 antigen - metabolism (342) 342
antibodies, monoclonal - therapeutic use (295) 295
mice (295) 295
male (278) 278
pd-l1 (265) 265
immunology (254) 254
immunotherapy - methods (241) 241
antineoplastic agents - therapeutic use (240) 240
pd-1 (238) 238
programmed cell death 1 receptor - immunology (229) 229
ctla-4 antigen - antagonists & inhibitors (226) 226
nivolumab (215) 215
tumors (214) 214
apoptosis (208) 208
lymphocytes (207) 207
expression (204) 204
cell line, tumor (195) 195
melanoma (185) 185
chemotherapy (184) 184
b7-h1 antigen - genetics (183) 183
pd-l1 protein (178) 178
middle aged (171) 171
neoplasms - immunology (170) 170
care and treatment (168) 168
ligands (167) 167
t cells (166) 166
treatment outcome (163) 163
aged (161) 161
programmed cell death 1 receptor - metabolism (154) 154
molecular targeted therapy (152) 152
immune checkpoint (146) 146
lymphocytes t (146) 146
antibodies, monoclonal - pharmacology (144) 144
open-label (143) 143
pd-1 protein (143) 143
antineoplastic agents - pharmacology (140) 140
adult (139) 139
mice, inbred c57bl (139) 139
pembrolizumab (139) 139
lung neoplasms - drug therapy (137) 137
antineoplastic agents, immunological - therapeutic use (136) 136
blockade (134) 134
neoplasms - drug therapy (133) 133
article (131) 131
ipilimumab (128) 128
metastasis (128) 128
safety (127) 127
b7-h1 (123) 123
prognosis (122) 122
t-cells (120) 120
t-lymphocytes - immunology (120) 120
therapy (116) 116
research (115) 115
abridged index medicus (114) 114
lung cancer (114) 114
carcinoma, non-small-cell lung - drug therapy (112) 112
health aspects (111) 111
clinical trials as topic (108) 108
cancer therapies (107) 107
patients (105) 105
b7-h1 antigen (102) 102
analysis (100) 100
antibodies, monoclonal, humanized - therapeutic use (98) 98
signal transduction - drug effects (98) 98
antibody (97) 97
cell death (97) 97
immunohistochemistry (95) 95
dendritic cells (94) 94
neoplasms - therapy (94) 94
activation (92) 92
ctla-4 antigen - immunology (92) 92
clinical trials (91) 91
antigens (90) 90
lung neoplasms - immunology (89) 89
lung neoplasms - pathology (89) 89
cd8-positive t-lymphocytes - immunology (88) 88
pd-1 blockade (88) 88
gene expression (87) 87
hematology (87) 87
immune response (87) 87
antibodies (86) 86
antineoplastic combined chemotherapy protocols - therapeutic use (86) 86
cell biology (86) 86
survival (86) 86
tumor microenvironment (86) 86
disease models, animal (85) 85
medical research (85) 85
aged, 80 and over (83) 83
biomarkers (83) 83
immunity (82) 82
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1218) 1218
French (17) 17
Chinese (8) 8
Czech (8) 8
German (3) 3
Italian (1) 1
Japanese (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 373 - 377
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, pp. e83139 - e83139
CD28, CTLA-4 and PD-L1, the three identified ligands for CD80/86, are pivotal positive and negative costimulatory molecules that, among other functions,... 
IN-VITRO | ACTIVATION | DENDRITIC CELLS | TCR STOP-SIGNAL | TOLERANCE | MULTIDISCIPLINARY SCIENCES | EXTRINSIC CONTROL | ANTI-CD28 ANTIBODY | UP-REGULATION | CUTTING EDGE | LYMPHOCYTES | B7-1 Antigen - antagonists & inhibitors | Cell Communication - immunology | B7-2 Antigen - genetics | B7-1 Antigen - genetics | Dendritic Cells - immunology | Humans | Molecular Targeted Therapy | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Cytotoxic - drug effects | CD28 Antigens - genetics | Protein Binding - drug effects | CD28 Antigens - antagonists & inhibitors | T-Lymphocytes, Regulatory - cytology | Dendritic Cells - drug effects | B7-2 Antigen - immunology | T-Lymphocytes, Cytotoxic - immunology | Gene Expression | B7-2 Antigen - antagonists & inhibitors | B7-1 Antigen - immunology | Antibodies, Monoclonal - pharmacology | CTLA-4 Antigen - genetics | CD28 Antigens - immunology | CTLA-4 Antigen - immunology | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Cell Movement - drug effects | T-Lymphocytes, Regulatory - drug effects | B7-H1 Antigen - antagonists & inhibitors | Lymphocyte Activation - drug effects | Cell Communication - drug effects | Dendritic Cells - cytology | CTLA-4 Antigen - antagonists & inhibitors | T-Lymphocytes, Cytotoxic - cytology | Viral antibodies | Antibodies | Antigens | B cells | T cells | Motility | Transplants & implants | Calcium | Blocking antibodies | Homeostasis | Effector cells | Reversing | Immunological synapses | Lymphocytes T | Kinases | CD28 antigen | T-cell receptor | CTLA-4 protein | Cell activation | Immunology | Lymphocytes | Dwell time | Cell cycle | Cytokines | Immunoregulation | CD80 antigen | T cell receptors | Costimulator | Microscopy | Antigen-presenting cells | PD-L1 protein | Ligands | Cell migration | Synapses | Apoptosis | Index Medicus | Life Sciences | Human health and pathology
Journal Article
Nature Communications, ISSN 2041-1723, 08/2016, Volume 7, Issue 1, pp. 12624 - 12624
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7693, pp. 544 - 548
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients... 
METASTATIC MELANOMA | CTLA-4 BLOCKADE | BLADDER-CANCER | THERAPY | LANDSCAPE | SUBTYPES | UROTHELIAL CARCINOMA | MULTIDISCIPLINARY SCIENCES | GENES | ADAPTIVE IMMUNE RESISTANCE | MPDL3280A | CD8-Positive T-Lymphocytes - cytology | Humans | Antibodies, Monoclonal - therapeutic use | Urothelium - pathology | Urologic Neoplasms - pathology | Neoplasm Metastasis | Urologic Neoplasms - drug therapy | Urologic Neoplasms - genetics | Immunotherapy | Antibodies - immunology | Antigens, Neoplasm - metabolism | Transforming Growth Factor beta - antagonists & inhibitors | Antigens, Neoplasm - analysis | Disease Models, Animal | Fibroblasts - metabolism | Antibodies - therapeutic use | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - pharmacology | Treatment Outcome | B7-H1 Antigen - immunology | Urologic Neoplasms - immunology | Antibodies - pharmacology | Tumor Microenvironment - immunology | Collagen - metabolism | Phenotype | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | CD8-Positive T-Lymphocytes - drug effects | Urothelium - immunology | Mice | Mutation | CD8-Positive T-Lymphocytes - immunology | Urothelium - drug effects | Transforming Growth Factor beta - metabolism | Cohort Studies | Drug Resistance, Neoplasm - drug effects | PD-1 protein | CD8 antigen | Transforming growth factor-a | Antibodies | Parenchyma | Lymphocytes T | Metastasis | Immunity | Metastases | Genotype & phenotype | Signal transduction | Lymphocytes | Cell cycle | Fibroblasts | Growth factors | Urothelial cancer | Phenotypes | Cytokines | Melanoma | Blocking | Gene expression | Patients | Generalized linear models | Signaling | Stromal cells | Medical prognosis | Collagen | PD-L1 protein | Ligands | Determinants | Infiltration | Cancer | Tumors | Apoptosis | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4242 - 4250
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 17, pp. 1627 - 1639
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 06/2015, Volume 10, Issue 6, pp. 910 - 923
Epidermal growth factor receptor (EGFR) mutation status was reported to be associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular... 
PD-L1 | NSCLC | PD-1 | EGFR | Tyrosine kinase inhibitors | LUNG | CELLS | B7-H1 EXPRESSION | DEATH-LIGAND 1 | MELANOMA | ONCOLOGY | PATHWAY | IMMUNOTHERAPY | RESPIRATORY SYSTEM | POOR-PROGNOSIS | GROWTH | INHIBITORS | Tumor Escape - drug effects | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Sequence Deletion | Up-Regulation | Exons | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | T-Lymphocytes - pathology | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - immunology | Lung Neoplasms - enzymology | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Programmed Cell Death 1 Receptor - metabolism | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Apoptosis - immunology | B7-H1 Antigen - antagonists & inhibitors | Interferon-gamma - immunology | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | T-Lymphocytes - immunology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | Interferon-gamma - biosynthesis | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 11/2014, Volume 515, Issue 7528, pp. 563 - 567
Journal Article